Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clemastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clemastine SCHEMBL23785539 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL727373 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4058472 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL23785540 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4178 | 1.00 | CHRM3 (1.00) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL932384 | 0.99 | CHRM3 (0.98) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL8144354 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL13740733 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088016 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 | |
| Clemastine SCHEMBL4088154 | 0.93 | CHRM3 (0.87) | CHRM3ADRA1AHRH3CYP3A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352626-A1 | IMMUNE TOLERANCE INDUCTION TO VIRAL CAPSIDS | UNIV FLORIDA (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250195694-A1 | METHODS AND COMPOSITIONS FOR TREATING TNNT2 RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-19 | — | — | US | disclosed |
| US-20250019722-A1 | COMPOSITIONS COMPRISING KOZAK SEQUENCES SELECTED FOR ENHANCED EXPRESSION | AAVANTIBIO INC (US) | 2025-01-16 | — | — | US | disclosed |
| CN-115175637-A | Rumen device | 阿根塔创新有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210308048-A1 | EUTECTIC SOLVENTS COMPRISING PHARMACEUTICAL AGENTS, AND METHODS OF MAKING AND USE THEREOF | Novilla Pharmaceuticals, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| US-9925202-B2 | Treatment of lymphangioleiomyomatosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925202-B2 | Treatment of lymphangioleiomyomatosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094457-A2 | SUBSTITUTED BENZHYDRYLETHERS | AUSPEX PHARMACEUTICALS (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071279-A1 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC DISORDERS | PINK1, PC, PCK2 | HRH1 2432/4885CHRM3 1278/4885ADRA1A 1637/4885 |
| US-10322122-B2 | Methods and compositions for treating degenerative and ischemic disorders | PINK1, PC, PCK2 | HRH1 2432/4885CHRM3 1278/4885ADRA1A 1637/4885 |
| US-20210308048-A1 | EUTECTIC SOLVENTS COMPRISING PHARMACEUTICAL AGENTS, AND METHODS OF MAKING AND USE THEREOF | ACHE, CES2, ELANE | HRH1 1351/4885CHRM3 207/4885ADRA1A 2543/4885 |
| US-20090203763-A1 | SUBSTITUTED BENZHYDRYLETHERS | UGT2B7, CYP3A7, CYP3A43 | HRH1 265/4885CHRM3 2837/4885ADRA1A 764/4885 |
| US-20250352626-A1 | IMMUNE TOLERANCE INDUCTION TO VIRAL CAPSIDS | HAVCR2, MYD88, TLR3 | HRH1 2298/4885CHRM3 4774/4885ADRA1A 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.